Disease Landscape and Forecast Insights

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the development and progressive enlargement of fluid-filled cysts in the kidneys. Particularly in the…

The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx…

The multiple sclerosis (MS) therapy market continues to evolve with each new FDA-approved disease-modifying therapy (DMT) further expanding treatment choice. The newest entrants (e.g., Kesimpta,…

Immune checkpoint inhibitors have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of…

The availability of multiple targeted therapies with diverse mechanisms of action, including biologics / biosimilars and oral agents, along with conventional treatments, makes the rheumatoid…

Chemotherapy has formed the backbone of oncology treatment for decades, and it continues to remain a critical cornerstone of antineoplastic drug therapy. The chemotherapy market is heavily…

Biosimilars referencing Roche/Genentech’s portfolio of blockbuster oncology monoclonal antibodies—Avastin, Herceptin, and Rituxan—launched in the United States throughout the second half of…

The schizophrenia therapy market is dominated by oral and long-acting injectable (LAI) antipsychotics, which are primarily effective in treating positive symptoms. However, in late 2019, the U.S…

More than two dozen antiepileptic drugs (AEDs) are available in the United States, yet approximately one-third of epilepsy patients are refractory to AED treatment. Opportunity in this arena has…

The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years…

Novartis’s Beovu (brolucizumab-dbll) was the fourth vascular endothelial growth factor (VEGF) inhibitor to launch for the treatment of wet age-related macular degeneration (AMD) in the United…